Medestea Research & Production

Medestea Research & Production was an Italian private pharmaceutical and biotechnology company based in Turin, Italy, founded in 2001. The company appears to have focused on pharmaceutical research, diagnostics-related activities, and development of proprietary therapeutic products, including an HIV-related program centered on the p17 matrix protein and an inhaled aspirin study in asthma. Available pipeline data indicate a very limited proprietary portfolio, with AT-96 emerging as its best-known program; that asset was later discontinued. The company was also associated with broader Medestea group activities in nutraceuticals and healthcare products, but Medestea Research & Production itself appears to have served as the R&D-focused entity. Corporate records indicate the company entered bankruptcy proceedings in 2017 and is no longer active.